Previous Close | 0.2870 |
Open | 0.2900 |
Bid | 0.2840 x N/A |
Ask | 0.2900 x N/A |
Day's Range | 0.2810 - 0.2900 |
52 Week Range | 0.2700 - 0.6640 |
Volume | |
Avg. Volume | 38,177 |
Market Cap | 7.469M |
Beta (5Y Monthly) | -0.51 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.40 |
BBS-Bioactive Bone Substitutes Plc, Company announcement, 6 March 2024 at 11:15 a.m. Changes in the BBS-Bioactive Bone Substitutes Plc’s Management Team Oy Jamerco Ltd. has terminated its service contract with BBS-Bioactive Bone Substitutes Ltd (“BBS”). As a result, Jari Kortesluoma’s position as the CFO and member of the management team will end. Kortesluoma will fulfill the responsibilities of CFO throughout the two-month notice period. BBS is currently in the process of searching for a new in
BBS-Bioactive Bone Substitutes Plc, Financial Statements Bulletin 2023, 26 February 2024 at 5.45 p.m. (EET) This is a summary of BBS-Bioactive Bone Substitutes Plc’s Financial Statements Bulletin for January–December 2023. The entire report is attached to this Company Announcement as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc’s website at https://www.bbs-artebone.fi/. Preparations for commercial phase initiated JULY-DECEMBER HIGHLIGHTS In the second half of 20